soul trial oral semaglutide cardiovascular outcomes 2024 results nejm 2025 Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed Semaglutide cardiovascular outcomes align more

Taking the full suggested intake of three capsules daily (1,500mg) falls within the dose range commonly used in studies exploring blood sugar control, metabolism and appetite regulation, making it a solid option for metabolic support

Over a median follow-up of 365 days, 17 tirzepatide patients and 33 control patients experienced suicidal ideation or attempts

This medication is not instant weight loss

You may have witnessed the excitement surrounding the new classes of medications being used for weight loss: GLP-1 receptor agonists, like Wegovy and Ozempic, and the newer, dual action (GLP1/GIP) medications like Mounjaro and Zepbound